Biogen Idec/Samsung's biologics JV begins life as Samsung Bioepis
This article was originally published in Scrip
Executive Summary
Biogen Idec and Samsung Biologics have now formally established their South Korean joint venture for biologics following the basic agreement for the $300 million operation reached in December.